BLA #3 they will have an adult trial, 6 year survival data and better manufacturing. It is time to bring in external Legal along the journey and 'minute' every conversation with the FDA. Decisions taken by Mesoblast made on interpretation in discussions with the FDA should be peer reviewed by someone other than MSB staff. Better lobbyists with Congress also needed. Lets hope SI acknowledges that these were his mistakes which has led to rejection #2 and learn from them. There can be no mistake #3 or it will be curtains.
Pretty obvious from this point forward, follow the money. If shorts and their merry band of posters become more relentless then we know their agenda is to cripple the Company in order to force a sell off on the IP. Small redemptions going forward from SI, get funding sorted quickly, keep to timelines and leave nothing to interpretation.
MSB Price at posting:
47.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)